Viktor Magdolen Selected Research

Urokinase-Type Plasminogen Activator (Urokinase)

11/2016	Preclinical evaluation of [111 In]MICA-401, an activity-based probe for SPECT imaging of in vivo uPA activity.
4/2015	Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221.
12/2014	Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
4/2014	Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
1/2014	Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.
12/2012	Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
6/2011	Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
6/2011	Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
11/2010	Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
10/2010	Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Viktor Magdolen Research Topics

Disease

82	Neoplasms (Cancer) 01/2022 - 01/2002
27	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 09/2002
27	Breast Neoplasms (Breast Cancer) 12/2021 - 01/2003
18	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2002
7	Triple Negative Breast Neoplasms 10/2021 - 01/2017
7	Disease Progression 12/2020 - 03/2005
7	Prostatic Neoplasms (Prostate Cancer) 11/2020 - 04/2010
6	Residual Neoplasm 01/2020 - 12/2016
3	Ascites 01/2021 - 01/2019
3	Inflammation (Inflammations) 01/2018 - 01/2004
2	Ovarian Epithelial Carcinoma 12/2021 - 08/2006
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2018
2	Melanoma (Melanoma, Malignant) 01/2018 - 10/2017
2	Carcinogenesis 01/2017 - 09/2014
2	Colonic Neoplasms (Colon Cancer) 09/2014 - 03/2010
2	Sarcoma (Soft Tissue Sarcoma) 06/2013 - 06/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2021
1	Adenocarcinoma 08/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018
1	Cognitive Dysfunction 01/2018
1	Dementia (Dementias) 01/2018

Drug/Important Bio-Agent (IBA)

40	Peptide Hydrolases (Proteases)FDA Link 08/2021 - 12/2002
30	Proteins (Proteins, Gene)FDA Link 08/2021 - 11/2002
29	Messenger RNA (mRNA)IBA 12/2021 - 04/2003
29	Kallikreins (Kallikrein)IBA 08/2021 - 03/2010
25	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2016 - 01/2002
24	Serine Proteases (Serine Protease)IBA 11/2019 - 01/2002
21	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2006
13	Plasminogen Activator Inhibitor 1IBA 11/2016 - 01/2002
10	AntigensIBA 01/2021 - 03/2004
9	Tissue Kallikreins (Tissue Kallikrein)IBA 10/2018 - 02/2006
8	Urokinase Plasminogen Activator ReceptorsIBA 06/2011 - 11/2002
7	Tumor Biomarkers (Tumor Markers)IBA 01/2021 - 10/2010
6	rat KLK7 proteinIBA 10/2020 - 01/2014
6	Tissue ExtractsIBA 01/2017 - 03/2004
6	PlasminogenIBA 10/2010 - 01/2002
5	Fibrinolysin FDA Link 01/2017 - 11/2002
4	AnthracyclinesIBA 10/2021 - 01/2017
4	LigandsIBA 01/2019 - 11/2002
4	Plasminogen InactivatorsIBA 11/2010 - 01/2002
3	Biological ProductsIBA 12/2021 - 01/2006
3	Matrix Metalloproteinases (MMPs)IBA 01/2019 - 07/2003
3	SteroidsIBA 01/2017 - 08/2006
3	Hormones (Hormone)IBA 01/2017 - 08/2006
3	EnzymesIBA 12/2014 - 02/2006
3	Paclitaxel (Taxol)FDA LinkGeneric 02/2014 - 12/2012
3	IntegrinsIBA 10/2013 - 01/2006
3	matrigelIBA 08/2012 - 07/2003
3	Extracellular Matrix ProteinsIBA 08/2012 - 02/2008
3	Peptides (Polypeptides)IBA 01/2008 - 09/2002
3	Cell Surface ReceptorsIBA 02/2003 - 01/2002
3	Cyclic PeptidesIBA 01/2003 - 09/2002
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
2	MicroRNAs (MicroRNA)IBA 01/2021 - 04/2015
2	Indicators and Reagents (Reagents)IBA 07/2019 - 01/2019
2	EpitopesIBA 01/2019 - 11/2002
2	Transcription Factors (Transcription Factor)IBA 11/2018 - 01/2017
2	Formaldehyde (Formol)FDA Link 03/2018 - 01/2017
2	ParaffinIBA 03/2018 - 01/2017
2	Pharmaceutical PreparationsIBA 01/2018 - 04/2005
2	hepsinIBA 01/2017 - 04/2014
2	Estrogen ReceptorsIBA 01/2017 - 08/2012
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2016 - 02/2006
2	RNA (Ribonucleic Acid)IBA 01/2014 - 09/2008
2	Biological FactorsIBA 11/2011 - 03/2004
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 02/2003
2	AntibodiesIBA 04/2010 - 01/2003
2	Tiopronin (Thiola)FDA Link 04/2010 - 05/2007
2	FibrinIBA 12/2008 - 09/2004
2	DNA (Deoxyribonucleic Acid)IBA 10/2008 - 03/2005
2	N- alpha- (2,4,6- triisopropyl- phenylsulfonyl)- 3- amidino- (L)- phenyl- alanine- 4- ethoxycarbonyl- piperazide hydrochlorideIBA 04/2005 - 02/2003
2	Silicon Dioxide (Silica)FDA LinkGeneric 01/2003 - 01/2002
1	Chemokine CXCL9IBA 01/2022
1	Transfer RNA (tRNA)IBA 12/2021
1	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2021
1	GTP-Binding Proteins (G-Protein)IBA 12/2021
1	Chemokine CX3CL1IBA 01/2021
1	Trastuzumab (Herceptin)FDA Link 01/2021
1	PlatinumIBA 12/2020
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2019
1	Serine (L-Serine)FDA Link 01/2019
1	Chemokine ReceptorsIBA 01/2019
1	CathepsinsIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	ChemokinesIBA 01/2019
1	Amino Acids FDA Link 01/2018
1	Monomeric GTP-Binding ProteinsIBA 01/2017
1	Progesterone FDA LinkGeneric 01/2017
1	AngiostatinsIBA 01/2017
1	Estrogens (Estrogen)FDA Link 01/2017
1	kallikrein 4IBA 01/2017
1	Mucin-1 (CA 15-3 Antigen)IBA 01/2017
1	phosphoserine aminotransferase (phosphoserine transaminase)IBA 01/2017
1	Tamoxifen FDA LinkGeneric 01/2017

Therapy/Procedure

19	Therapeutics 01/2022 - 01/2002
8	Drug Therapy (Chemotherapy) 12/2021 - 12/2016
2	Adjuvant Chemotherapy 03/2018 - 03/2004
1	Immunotherapy 01/2019
1	Combination Drug Therapy (Combination Chemotherapy) 01/2017